InsidersTradesSigma
Track the NanoVibronix, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Technology sector, NanoVibronix, Inc. has recorded 5 insider filings. Market capitalisation: €1,096.4bn. The latest transaction was disclosed on 5 January 2023 (Acquisition). Among the most active insiders: FASHEK CHRISTOPHER M. Every trade is openly available.
5
Insider Decl.
n/a
Thresholds
€83,194
5 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NanoVibronix, Inc. Strong Buy (bullish), based on 42 analysts. Average price target: US$1,491.95.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,828 of 29,063 companies
71.3
score / 100
Value64
Quality79
FCF yld1.2%
Earn yld6.4%
EV/EBITDA8.1x
ROE67%
Gross mgn40%
Net mgn23%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 January 2023
Declarations5 total
50,000 shares@ US$0.25100.0% of flowCommon StockSEC:0001493152-23-000609:0
Canonical exit: 5 Apr 2023 (T+90)
40,000 shares@ US$0.59570.0000% mcap33.6% of flowCommon StockSEC:0001493152-22-017169:0
Canonical exit: 13 Sept 2022 (T+90)
25,000 shares@ US$2.000.0000% mcap66.4% of flowCommon StockSEC:0001493152-22-017164:0
Canonical exit: 18 Feb 2020 (T+90)
4,000 shares@ US$0.57390.0000% mcap100.0% of flowCommon StockSEC:0001493152-22-016736:0
Canonical exit: 12 Sept 2022 (T+90)
2,000 shares@ US$0.690.0000% mcap100.0% of flowCommon StockSEC:0001493152-22-015656:0
Canonical exit: 30 Aug 2022 (T+90)
5 of 5 declarations
关于 NanoVibronix, Inc.
NanoVibronix, Inc. 是一家科技公司，专注于开发利用超声波振动技术的医疗设备。该公司在纳斯达克上市，股票代码为 NVIV。